Vol 8, Supplement 3 (July 16, 2019): Translational Andrology and Urology

Editorial

Targeting the adipose tissue to fight prostate cancer

Silvano Paternoster, Marco Falasca

PDF Pages: S229-S231 Full Text (1119) Open Access

Salvage prostate brachytherapy after definitive external radiation: tried and now tested

Young Kwok, Mannat Narang, Jason K. Molitoris

PDF Pages: S232-S235 Full Text (2140) Open Access

Biomarkers for platinum sensitivity in bladder cancer: are we there yet?

Nirmish Singla, Rashed A. Ghandour, Ganesh V. Raj

PDF Pages: S236-S239 Full Text (1060) Open Access

Role of heat shock proteins in bladder cancer: potential biomarkers for treatment response and oncological prognosis

Jorge Daza, Zeynep Gul, John P. Sfakianos

PDF Pages: S240-S241 Full Text (857) Open Access

Adipose tissue: enabler of prostate cancer aggressive behavior

Cameron A. Wade, Natasha Kyprianou

PDF Pages: S242-S245 Full Text (1296) Open Access

Dietary intake and prostate cancer, continued pursuit for evidence

Pao-Hwa Lin, Stephen J. Freedland

PDF Pages: S246-S249 Full Text (1584) Open Access

Coping with chemoresistance in prostate cancer—co-targeting of adipose stromal cells?

Divya Bhagirath, Sharanjot Saini

PDF Pages: S250-S253 Full Text (1125) Open Access

A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer

Archana Agarwal, Guru Sonpavde

PDF Pages: S254-S256 Full Text (1140) Open Access

Editorial Commentary

Long term results of the NRG/RTOG 9413: a key study but one of the most confusing study in prostate cancer radiotherapy!

Pascal Pommier

PDF Pages: S257-S260 Full Text (1501) Open Access

Association between perioperative morbidity and mortality after radical cystectomy: an opportunity to understand the complication snowball effect

Vignesh T. Packiam, Joseph J. Pariser

PDF Pages: S261-S262 Full Text (1400) Open Access

Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?

Jaspreet S. Batra, Kenneth J. Pienta, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe

PDF Pages: S263-S264 Full Text (1502) Open Access

Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526)

Randall J. Brenneman, Edward Soffen, Hiram A. Gay, Peter F. Orio III, John P. Christodouleas, John C. Baumann, Brian C. Baumann

PDF Pages: S265-S270 Full Text (1380) Open Access

Experience of surgeon, hospital, and comprehensive cancer team critical to the outcomes of radical cystectomy and urinary diversion

Ram Anil Pathak, Ashok Kumar Hemal

PDF Pages: S271-S273 Full Text (882) Open Access

Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?

Moritz Maas, Arnulf Stenzl

PDF Pages: S274-S276 Full Text (983) Open Access

The clinical and economic burden of perioperative complications of radical cystectomy

Christine W. Liaw, Jared S. Winoker, Peter Wiklund, John Sfakianos, Matthew D. Galsky, Reza Mehrazin

PDF Pages: S277-S279 Full Text (858) Open Access

Adjuvant chemotherapy in bladder cancer patients with histological variants: time to change the approach?

Luca Afferi, Stefania Zamboni, Philipp Baumeister, Livio Mordasini, Agostino Mattei, Marco Moschini

PDF Pages: S280-S282 Full Text (1127) Open Access

Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?

Günter Niegisch

PDF Pages: S283-S286 Full Text (893) Open Access

Changes in testosterone prescribing patterns after FDA warning

Soum D. Lokeshwar, Joshua Bitran, Ranjith Ramasamy

PDF Pages: S287-S288 Full Text (1233) Open Access

Perioperative mortality following radical cystectomy: the slippery slope of complications

Marc H. Nelson, Marcus L. Quek

PDF Pages: S289-S290 Full Text (846) Open Access

Prognostic impact of tumor infiltrating lymphocytes in bladder urothelial carcinoma

Hyung Suk Kim, Ja Hyeon Ku

PDF Pages: S291-S292 Full Text (1510) Open Access

Molecular subtypes and response to immunotherapy in bladder cancer patients

Tilman Todenhöfer, Roland Seiler

PDF Pages: S293-S295 Full Text (1470) Open Access

Editorial: assessment of ⁶⁸Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer, a prospective single arm clinical study: California shows the way!

Peter Choyke

PDF Pages: S296-S299 Full Text (1325) Open Access

Bladder organoids: a step towards personalised cancer therapy?

Sreemoti Banerjee, Jennifer Southgate

PDF Pages: S300-S302 Full Text (2111) Open Access

The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer

Mark D. Hurwitz

PDF Pages: S303-S306 Full Text (1264) Open Access

Editorial: early PSA-testing after radical prostatectomy—the truth behind the scenes

Julian Hanske, Florian Roghmann, Joachim Noldus, Marko Brock

PDF Pages: S307-S309 Full Text (2547) Open Access

Establishing and characterization of human and murine bladder cancer organoids

Neveen Said

PDF Pages: S310-S313 Full Text (1632) Open Access

Studying the impact of comorbidity on post radical cystectomy survival: have we come a full circle?

Subodh K. Regmi, Badrinath R. Konety

PDF Pages: S314-S317 Full Text (1069) Open Access

The diagnosis of bladder cancer: are we missing a teachable moment for smoking cessation?

Arthur E. Frankel, Sachin Pai, William Taylor, Marcus Chuan Beng Tan

PDF Pages: S318-S321 Full Text (1149) Open Access

Looking into the clinical application of CD47-targeted near-infrared photoimmunotherapy for human bladder cancer treatment

Jayoung Kim

PDF Pages: S322-S324 Full Text (1306) Open Access

Molecular subtyping, tumor infiltration, and trimodal therapy for muscle-invasive bladder cancer: more questions than answers

Ronald Kool, José João Mansure, Wassim Kassouf

PDF Pages: S325-S328 Full Text (1189) Open Access

How to guide the selection of patients for trimodality therapy: the case for tumor immune and stromal signature

Luca Boeri, R. Jeffrey Karnes, Emanuele Montanari

PDF Pages: S329-S331 Full Text (1190) Open Access

Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer

Makito Miyake, Takuya Owari, Shunta Hori, Kiyohide Fujimoto

PDF Pages: S332-S334 Full Text (1069) Open Access

Prognosis in high-grade T1 bladder cancer: host immune response and tumour infiltrating lymphocytes

Su-Min Lee

PDF Pages: S335-S336 Full Text (972) Open Access

The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer

Amir Sherif

PDF Pages: S337-S340 Full Text (1145) Open Access

Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale

Ramy Sedhom, Emmanuel S. Antonarakis

PDF Pages: S341-S345 Full Text (1806) Open Access

Letter to the Editor

An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?

Judith Bosschieter, R. Jeroen A. van Moorselaar, Jakko A. Nieuwenhuijzen

PDF Pages: S346-S347 Full Text (1070) Open Access

The role of adipose stroma in prostate cancer aggressiveness

Mikhail G. Kolonin, John DiGiovanni

PDF Pages: S348-S350 Full Text (1249) Open Access

Disclosure:

The supplement was published without any sponsorship or funding.